Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281294 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by PDL BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00281294 is a Phase 2 study that was terminated before completion, run by PDL BioPharma. The registered enrollment target is 40 participants.
The verdict
NCT00281294, a Phase 2 study, was terminated before completion, sponsored by PDL BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50% improvement of an American College of Rheumatology criteria (ACR50) response at Week 14 (Stage A of study).
Interventions
- DRUG Fontolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00281294
The ClinicalTrials.gov registry entry for NCT00281294 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PDL BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fontolizumab is the first listed.
NCT00281294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00281294 about?
NCT00281294 is a clinical study titled "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis". To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50% improvement of an American College of Rheumatology criteria (ACR50) response at Week 14 (Stage A of study).
What is the current status of trial NCT00281294?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-12. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00281294?
The interventions under investigation include: Fontolizumab (DRUG).
Who is sponsoring clinical trial NCT00281294?
This trial is sponsored by PDL BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.